Hemostemix Inc. (CVE:HEM – Get Free Report) fell 19.4% during trading on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares were traded during trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Performance
The firm has a market capitalization of C$21.13 million, a P/E ratio of -4.23 and a beta of 0.20. The stock has a fifty day simple moving average of C$0.20 and a two-hundred day simple moving average of C$0.12. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- Best Stocks Under $10.00
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
- The How and Why of Investing in Gold Stocks
- After Earnings, Is Transocean Stock the Best Energy Play?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
